UBS analyst Kevin Caliendo's revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy chain.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharmaceutical name to buy from neutral.
With CVS re-establishing forward guidance and offering a deeply discounted valuation, the balance of risk favors upside.
UBS sees shares of Cisco rallying 20% from their current levels.
Chart strategist Katie Stockton breaks down the technical backdrop in CVS.
The bank maintained its buy rating on the e-commerce giant and lifted its 12-month price target.
The bank upgraded shares of the glass manufacturer to buy from neutral.
